AYTU BIOPHARMA INC
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
AYTU$1.79-2.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
PART I - FINANCIAL INFORMATION Item 1. Financial Statements Unaudited Consolidated Balance Sheets
PART 1 - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
AYTU BIOPHARMA, INC.
UNAUDITED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
| March 31, | June 30, | |
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $19,760 | $22,985 |
| Accounts receivable, net | 29,925 | 28,937 |
| Inventories | 13,193 | 11,995 |
| Prepaid expenses | 7,249 | 8,047 |
| Other current assets | 1,003 | 868 |
| Total current assets | 71,130 | 72,832 |
| Non-current assets: | ||
| Property and equipment, net | 967 | 1,815 |
| Operating lease right-of-use assets | 1,795 | 2,054 |
| Intangible assets, net | 54,082 | 58,970 |
| Other non-current assets | 889 | 792 |
| Total non-current assets | 57,733 | 63,631 |
| Total assets | $128,863 | $136,463 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $10,475 | $13,478 |
| Accrued liabilities | 44,091 | 46,799 |
| Short-term line of credit | 1,581 | 1,563 |
| Current portion of debt | 15,135 | 85 |
| Current portion of derivative warrant liabilities | 3,261 | — |
| Other current liabilities | 9,146 | 7,090 |
| Total current liabilities | 83,689 | 69,015 |
| Non-current liabilities: | ||
| Debt, net of current portion | — | 14,713 |
| Derivative warrant liabilities | 8,609 | 6,403 |
| Other non-current liabilities | 5,788 | 6,975 |
| Total non-current liabilities | 14,397 | 28,091 |
| Commitments and contingencies (note 13) | ||
| Stockholders’ equity: | ||
| Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding | — | — |
| Common stock, par value $.0001; 200,000,000 shares authorized; 5,567,909 and 5,517,174 shares issued and outstanding, respectively | 1 | 1 |
| Additional paid-in capital | 346,132 | 343,485 |
| Accumulated deficit | (315,356) | (304,129) |
| Total stockholders’ equity | 30,777 | 39,357 |
| Total liabilities and stockholders’ equity | $128,863 | $136,463 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.